Drug Trial Radar · NCT07444385
A Study to Evaluate the Safety and Pharmacokinetics of AD-116 and AD-1161 in Healthy Adult Male Subjects
Last checked: Nov 20, 2026Latest source record: Mar 3, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
44
Planned (sponsor's estimate)
Start
Feb 26, 2026
Primary completion
Apr 22, 2026
Study completion May 8, 2026
Sponsor
- Lead sponsor
- Addpharma Inc.Industry
- Sponsor type
- Industry
- First posted
- Mar 2, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Crossover
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- Male only, from 19 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
A Study to Evaluate the Safety and Pharmacokinetics of AD-116 and AD-1161 Under Fed Conditions in Healthy Adult Male Subjects
Conditions
- Benign Prostatic Hyperplasia
Interventions
AD-116, AD-1161Drug
Single-dose oral administration of AD-116 or AD-1161, according to randomized sequence.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Area under the plasma concentration-time curve during dosing interval (AUCt)Time frame: pre-dose (0hour) to 72hours
- Maximum concentration of drug in plasma (Cmax)Time frame: pre-dose (0hour) to 72hours
Locations
1 site in 1 country. Site status is shown where the registry gives one.
H PLUS YANGJI HOSPITAL, Seoul
Seoul, South Korea · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.